Last reviewed · How we verify
BEBT-209 capsules
BEBT-209 capsules is a SGLT2 inhibitor Small molecule drug developed by BeBetter Med Inc. It is currently in Phase 3 development for Type 2 diabetes, Cardiovascular disease. Also known as: KCBT-0191, BEBT-209.
BEBT-209 capsules are a small molecule drug that targets the SGLT2 receptor.
BEBT-209 capsules are a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular disease.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BEBT-209 capsules |
|---|---|
| Also known as | KCBT-0191, BEBT-209 |
| Sponsor | BeBetter Med Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the SGLT2 receptor, BEBT-209 capsules reduce glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The drug's effects on blood glucose levels may also have secondary benefits for patients with cardiovascular disease.
Approved indications
- Type 2 diabetes
- Cardiovascular disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy (PHASE3)
- A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer (PHASE2)
- Phase I Study of BEBT-209 in Women With Advanced Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEBT-209 capsules CI brief — competitive landscape report
- BEBT-209 capsules updates RSS · CI watch RSS
- BeBetter Med Inc portfolio CI
Frequently asked questions about BEBT-209 capsules
What is BEBT-209 capsules?
How does BEBT-209 capsules work?
What is BEBT-209 capsules used for?
Who makes BEBT-209 capsules?
Is BEBT-209 capsules also known as anything else?
What drug class is BEBT-209 capsules in?
What development phase is BEBT-209 capsules in?
What are the side effects of BEBT-209 capsules?
What does BEBT-209 capsules target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: BeBetter Med Inc — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Indication: Drugs for Cardiovascular disease
- Also known as: KCBT-0191, BEBT-209
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing